Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1362 - Clinical implication of PLR and PD-L1 in breast cancer patients


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Breast Cancer


Shusen Wang


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


S. Wang1, Q. Lu2, T. Qin1, F. Xu1, Y. Zeng3, W. Xia1, Q. Zheng1, K. Lee1, K. Zhang1, G. Qin1, M.T. Kong4, R. Hong1, Y. Shi1, Z. Yuan1

Author affiliations

  • 1 Medical Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou/CN
  • 3 Breast Cencer, Sun Yat-sen Memorial Hospital, Guangzhou/CN
  • 4 Internal Medicine, Hospital Conde S. Januário, macau/MO


Abstract 1362


Anti-tumor action of the host immune systems and cancer-immune interaction are associated with tumor prognosis. Programmed death ligand-1 (PD-L1) expression was found as an unfavorable prognostic factor in breast cancer in our previous study. Besides, PD-L1 and biomarkers of the host immunity which included Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) have been reported in predicting prognosis of biliary tract cancer. However, combination of NLR/PLR and PD-L1 in breast cancer has not been reported. The aim of this study is to evaluate the prognostic role of NLR/PLR and PD-L1 in breast cancer.


A total of 870 patients with breast cancer treated in Sun Yat-Sen University Cancer Center from 2000 to 2012 with known PD-L1 status were included. Clinicopathological data and pretreatment complete blood count were retrospectively collected. X-tile was used to generate the optimal cut-off value of NLR and PLR. Kaplan-Meier and univariate Cox proportional hazards model analyses were used to compare the survival of patients between different groups.


High PLR group achieved worse result than low PLR group in OS and DFS (5-year OS rate: 82.6% vs 88.8%, p = 0.010; 5-year DFS rate: 78.7% vs 85.6%, p = 0.003). High PLR was associated with shorter DFS (adjusted HR = 1.540, 95%CI: 1.124-2.110, p = 0.007), while high PLR was not an independent factor for OS (adjusted HR = 1.001, 95%CI: 0.999-1.003, p = 0.488). NLR was not associated with patients’ survival outcome. And we found patients with PD-L1 expression and high PLR had the worst prognosis. The 5-year DFS rates were 68.4%, and 85.8% in high PLR+PD-L1 (+) group and low PLR+PD-L1 (-) group respectively (p = 0.002). The 5-year OS rates were 73.4% and 90.1%, respectively (p 


High PLR are associated with poor DFS in breast cancer patients. PD-L1 expression combined with high PLR was associated with an aggressive clinical outcome. Further studies are needed to evaluate the predictive value of combination of PD-L1 and peripheral blood immune markers.

Clinical trial identification

Legal entity responsible for the study

Shusen Wang


National Natural Science Foundation of China (81502302); Science and Technology Program of Guangdong Province (2014A020212384; 2016A020215079)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.